AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes
Trial of the Efficacy and Safety of High-dose Immunosuppressive Therapy Based on Fludarabine and Cyclophosphamide-containing Conditioning Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis.
What it found
No result yet.
What was tested
Treatment tested
- Fludarabine phosphate
DNA polymerase (alpha/delta/epsilon) inhibitor|Ribonucleoside-diphosphate reductase RR1 inhibitor
What it measured
Main measures
Multiple sclerosis progression free survival
365 days
Safety
Other measures (9)
Cumulative incidence of mortality
365 days
To evaluate adverse effects after FluCy200 conditioning regimen
365 days
SafetyQuality of life status 1
365 days
Mood and sleepQuality of life (reported by participants)Quality of life status 2
365 days
PainQuality of life (reported by participants)Quality of life status 3
365 days
Walking and mobilityQuality of life (reported by participants)Quality of life status 4
365 days
FatigueWalking and mobilityQuality of life (reported by participants)Neurological status 1
365 days
Disability progressionWalking and mobilityImmune reconstitution
365 days
Immune responseMagnetic resonance imaging response
365 days
MRI lesions
Who could take part
MS (type not specified) · 18 to 65
Show the full criteria
Inclusion criteria
* Age 18-65; * 1.0-6.5 points on the EDSS scale (for MS); * Length of illness - any; * Disease progression during the last 6 months while taking drugs of 1st and 2nd lines; * An established and confirmed diagnosis of an autoimmune disease in the previous stages of treatment; * Ineffectiveness, inaccessibility or intolerance of Disease-Modifying Therapies; * Relapse after AHSCT. * Absence of severe concomitant somatic pathology; * Left ventricular injection fraction > 50%; * Karnofsky Performance Score (KPS) > 30%; * The ability to take oral medications; * Life expectancy is more than 1 month; * Signed informed consent of the patient or legal representatives.
Exclusion criteria
* Moderate or severe cardiac dysfunction, left ventricular ejection fraction \<50% * Moderate or severe decrease in pulmonary function, FEV1 \<70% or DLCO\<70% of predicted * Respiratory distress >grade I * Severe organ dysfunction: AST or ALT >5 upper normal limits, bilirubin >1.5 upper normal limits, creatinine >2 upper normal limits * Creatinine clearance \< 60 mL/min * Uncontrolled bacterial or fungal infection at the time of enrollment * Requirement for vasopressor support at the time of enrollment * Karnofsky performans status \<30% * Pregnancy * Somatic or psychiatric disorder making the patient unable to sign informed consent
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
One of the possible options for the treatment of MS at present is a high-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HIST-AHSCT), which is a highly effective treatment for patients with relapsing-remitting MS. This method of MS treatment was introduced in 1997. Significant complications and mortality associated with HIST-ATHSC is an obstacle to broad use of this method. The risk is even greater in patients with advanced disease, long duration of previous treatment and aggressive forms of MS. Despite toxicity certain progressive cases of MS are still an indication for HIST-autoHSCT. Most commonly used conditioning regimens for multiple sclerosis include high-dose cyclophosphamide. One of the options to reduce cyclophosphamide-related toxicity and dose is addition of fludarabine. Fludarabine is a cytostatic drug, an antimetabolite from the group of purine antagonists. It has a pronounced immunosuppressive activity and no overlapping toxicity with cyclophosphamide. The study will evaluate the safety and efficacy of this combination.
Papers
Loading reviews and guidelines…
Related trials
- Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Scle
Phase 4 · Status unknown
No results found
- A phase IV, unicentric, open label clinical trial to evaluate the defa
Phase 4 · Withdrawn
Stopped
- Relationship Between Oral DMT Burden and Adherence in MS
Status unknown
No results found
- Physical and Cognitive Performance During the Two First Years of Lemtr
Completed
Paper found, not read
- Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers
Status unknown
Paper found, not read
- Observational Study of a Novel Peri Infusion Regimen on the Infusion A
Completed
No results found
History
Started
Oct 2020
Main results due
Oct 2025
Finished
Dec 2026